Probiotics, irritable bowel syndrome, and inflammatory bowel disease

被引:26
作者
Martin H. Floch
机构
[1] Yale University School of Medicine,Department of Medicine
关键词
Inflammatory Bowel Disease; Lactobacillus; Ulcerative Colitis; Irritable Bowel Syndrome; Lactobacillus Plantarum;
D O I
10.1007/s11938-003-0020-y
中图分类号
学科分类号
摘要
Probiotics are live, microbial food supplements that benefit the host animal by improving intestinal microbial balance. Their major role in preventing and treating gastrointestinal disease appears to be from their effect on the immune process, protection against abnormal invasive bacteria, and in the production of short-chain fatty acids from starch and non-starch polysaccharides. Probiotic microorganisms are administered in food supplements and yogurts. They are also now sold in the form of capsules and powders. There is great variation in the microorganisms in the various supplements. It is important to understand that all probiotic products are different. Some contain a single organism and others contain multiple organisms. Therapeutic results have been achieved with various probiotics in different diseases. In the treatment of inflammatory bowel diseases (IBD), success has been reported with Escherichia coli Nissle strain in ulcerative colitis, and with a multiple organism product, VSL#3 (VSL Pharmaceuticals, Fort Lauderdale, FL), in Crohn’s disease and pouchitis. Initial reports in irritable bowel syndrome (IBS) have resulted in encouraging results with the use of E. coli Nissle strain, and recently with multiple organism probiotic supplements. However, caution must still apply to the use of probiotics in IBD and IBS because the reports and the number of patients treated are limited.
引用
收藏
页码:283 / 288
页数:5
相关论文
共 94 条
[1]  
Floch MH(2001)Probiotics and functional foods in gastrointestinal disorders Curr Gastro Rep 3 343-350
[2]  
Hong-Curtiss J(2001)Taxonomy and important features of probiotic microorganisms in food and nutrition Am J Clin Nutr 73 365S-373S
[3]  
Holzapfel WH(2001)The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic J Dairy Sci 84 319-331
[4]  
Haberer P(2000)Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial Gastroenterology 119 305-309
[5]  
Geisen R(2000)Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome Am J Gastroenterol 95 1231-1238
[6]  
Sanders ME(2001)Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine Gastroenterology 120 A127-A127
[7]  
Klaenhammer TR(2001)Probiotics: effects on immunity Am J Clin Nutr 73 444S-450S
[8]  
Gionchetti P(1999)Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease Gastroenterology 117 761-769
[9]  
Rizzello F(2002)Increased mucosal tumour necrosis factor z production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria Gut 51 659-664
[10]  
Venturi A(2003)Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease Hepatology 37 1-9